Source - RNS
RNS Number : 6034A
Bank of America Merrill Lynch
22 January 2020
 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

1.

KEY INFORMATION

Name of exempt principal trader

BofA Securities, Inc.

Company dealt in

AbbVie Inc

Class of relevant security to which the
dealings being disclosed relate(Note 1)

Common - US00287Y1091

Date of dealing

21/01/2020

 

2.

INTERESTS AND SHORT POSITIONS

(a)

Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)

Class of relevant security: Common

US00287Y1091


Long

Short

Number

%

Number

%

(1)

Relevant securities

403,401

0.027%

2,517,873

0.17 %

(2)

Derivatives (other than options):

1,745,771

0.118%

415,978

0.028%

(3)

Options and agreements to purchase/sell:

58,100

0.004%

57,500

0.004%

Total

2,207,272

0.149%

2,991,351

0.202%

 

(b)

Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)

Class of relevant security:



Long

Short

Number

%

Number

%

(1)

Relevant securities

0

0%

0

0%

(2)

Derivatives (other than options):

0

0%

0

0%

(3)

Options and agreements to purchase/sell:

0

0%

0

0%

Total

0

0%

0

0%

3.

DEALINGS (Note 3)

(a)

Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Purchase

         369

 87.6 USD

 Purchase

      1,854

 87.867 USD

 Purchase

      1,000

 87.95 USD

 Purchase

      7,610

 87.99 USD

 Purchase

      1,199

 88 USD

 Purchase

         229

 88.072 USD

 Purchase

         100

 88.09 USD

 Purchase

         100

 88.12 USD

 Purchase

         573

 88.13 USD

 Purchase

          71

 88.139 USD

 Purchase

      2,016

 88.14 USD

 Purchase

         662

 88.15 USD

 Purchase

         260

 88.17 USD

 Purchase

         240

 88.2 USD

 Purchase

      1,948

 88.21 USD

 Purchase

      1,482

 88.22 USD

 Purchase

      1,788

 88.23 USD

 Purchase

         100

 88.235 USD

 Purchase

         100

 88.239 USD

 Purchase

      2,611

 88.24 USD

 Purchase

          84

 88.245 USD

 Purchase

      2,862

 88.25 USD

 Purchase

         902

 88.26 USD

 Purchase

          87

 88.265 USD

 Purchase

         287

 88.27 USD

 Purchase

         286

 88.28 USD

 Purchase

         388

 88.29 USD

 Purchase

         100

 88.315 USD

Purchase

      177,351

 87.99 USD

Purchase

      100

 88.055 USD

 

Purchase/sale

Number of relevant securities

Price per unit (Note 4)

Sale

         100

 87.57 USD

 Sale

         369

 87.6 USD

 Sale

          59

 87.66 USD

 Sale

         100

 87.661 USD

 Sale

         100

 87.67 USD

 Sale

         455

 87.73 USD

 Sale

         200

 87.74 USD

 Sale

         100

 87.75 USD

 Sale

         474

 87.76 USD

 Sale

         100

 87.77 USD

 Sale

            8

 87.81 USD

 Sale

          42

 87.83 USD

 Sale

          52

 87.84 USD

 Sale

         200

 87.86 USD

 Sale

         100

 87.865 USD

 Sale

         357

 87.87 USD

 Sale

         500

 87.885 USD

 Sale

         629

 87.89 USD

 Sale

         100

 87.895 USD

 Sale

         151

 87.9 USD

 Sale

         486

 87.91 USD

 Sale

         300

 87.915 USD

 Sale

         679

 87.92 USD

 Sale

         794

 87.93 USD

 Sale

         200

 87.935 USD

 Sale

      2,075

 87.94 USD

 Sale

         300

 87.945 USD

 Sale

      3,289

 87.95 USD

 Sale

         100

 87.955 USD

 Sale

      2,663

 87.96 USD

 Sale

      1,616

 87.965 USD

 Sale

      2,559

 87.97 USD

 Sale

         216

 87.975 USD

 Sale

      1,787

 87.98 USD

 Sale

         274

 87.985 USD

 Sale

  201,930

 87.99 USD

 Sale

          89

 87.995 USD

 Sale

         934

 88 USD

 Sale

         117

 88.01 USD

 Sale

         566

 88.02 USD

 Sale

         144

 88.03 USD

 Sale

         292

 88.04 USD

 Sale

         151

 88.05 USD

 Sale

          33

 88.06 USD

 Sale

            1

 88.065 USD

 Sale

         127

 88.07 USD

 Sale

         155

 88.075 USD

 Sale

         390

 88.08 USD

 Sale

         171

 88.09 USD

 Sale

          15

 88.1 USD

 Sale

            2

 88.11 USD

 Sale

          16

 88.12 USD

 Sale

         261

 88.13 USD

 Sale

         300

 88.14 USD

 Sale

         290

 88.15 USD

 Sale

          90

 88.16 USD

 Sale

            5

 88.17 USD

 Sale

         130

 88.18 USD

 Sale

         256

 88.19 USD

 Sale

          42

 88.2 USD

 Sale

          56

 88.21 USD

 Sale

          46

 88.22 USD

 Sale

         254

 88.23 USD

 Sale

         131

 88.24 USD

 Sale

         456

 88.25 USD

 Sale

      4,608

 88.26 USD

 Sale

         100

 88.263 USD

 Sale

         400

 88.265 USD

 Sale

         954

 88.27 USD

 Sale

         500

 88.275 USD

 Sale

      1,041

 88.28 USD

 Sale

         188

 88.29 USD

 Sale

         686

 88.3 USD

 Sale

         100

 88.305 USD

 Sale

         329

 88.31 USD

 Sale

          33

 88.32 USD

 Sale

            2

 88.37 USD

Sale

                                     129

           87.99 USD

Sale

                                     952

            88 USD

 

 

(b)

Derivatives transactions (other than options transactions)

Product name,
e.g. CFD

Nature of transaction
(Note 5)

Number of relevant securities
(Note 6)

Price per unit
(Note 4)

Swaps

Reducing a Short Position

17,717

87.99 USD

Swaps

Increasing a Long Position

1,044

87.99 USD

Swaps

Reducing a Short Position

6,320

87.99 USD

Swaps

Increasing a Short Position

200

88.083 USD

Swaps

Increasing a Short Position

29

88.048 USD

 

(c)

Options transactions in respect of existing relevant securities

(i)

Writing, selling, purchasing or varying

Product name, e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc

Expiry date

Option money paid/ received per unit (Note 4)

N/A

N/A

N/A

N/A

N/A

N/A

N/A

 

(ii)

Exercising

Product name,
e.g. call option

Number of securities

Exercise price per
unit
(Note 4)

N/A

N/A

N/A

 

(d)

Other dealings (including transactions in respect of new securities) (Note 3)

Nature or transaction
(Note 7)

Details

Price per unit
(if applicable)
(Note 4)




Borrow

Borrow of 80,000 shares

N/A

Borrow

Borrow of 73,300 shares

N/A

Borrow

Borrow of 50,590 shares

N/A

 

4.

OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.

None

 

Is a Supplemental Form 38.5(b) attached? (Note 8)

Yes

 

Date of disclosure

22/01/2020

Contact name

Tolu Tade

Telephone number

+44207 996 3410

Name of offeree/offeror with which connected

AbbVie Inc

Nature of connection (Note 9)

Advisor to - AbbVie Inc

SUPPLEMENTAL FORM 38.5(b)


DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

Product name,
e.g. call option

Written or
purchased

Number of securities to which the option or derivative relates

Exercise price
(Note 2)

Type, e.g.
American,
European etc

Expiry date

Call Option

Written

           7,500

105 USD

 American

15/01/2021

Call Option

Purchased

         22,400

85 USD

 American

15/01/2021

Call Option

Purchased

         35,700

90 USD

 American

21/02/2020

Put Option

Written

         50,000

75 USD

 American

15/01/2021

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEUUUARRVUAUAR
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.